Drug Profile
DMT 200
Alternative Names: DMT 210; DMT 220; DMT200; SIG 990Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Signum Biosciences
- Developer Dermata Therapeutics; Signum Biosciences
- Class Anti-inflammatories; Skin disorder therapies; Small molecules; Terpenes
- Mechanism of Action G protein-coupled receptor antagonists; GTP-binding protein modulators; Interleukin 4 inhibitors; Interleukin 6 inhibitors; Interleukin-17 inhibitors; Toll like receptor 2 antagonists; Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis; Rosacea
- No development reported Acne vulgaris
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Acne-vulgaris in USA (Topical, Gel)
- 28 Mar 2021 No recent reports of development identified for research development in Rosacea in USA (Ophthalmic)
- 28 Feb 2017 Early research in Rosacea in USA (Ophthalmic) (Dermata Therapeutics pipeline, February 2017)